# Study Evaluating AGG-523 in Subjects With Osteoarthritis

> **NCT00427687** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** AGG-523

## Key facts

- **NCT ID:** NCT00427687
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** — (—)
- **Last updated:** 2008-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427687, "Study Evaluating AGG-523 in Subjects With Osteoarthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00427687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*